Mounjaro Sales Dip for the First Time: Is Semaglutide Taking Over India’s Weight-Loss Drug Market?

The Turning Point in India’s Obesity Drug Market

India’s pharmaceutical landscape is witnessing a fascinating shift. For months, one name dominated headlines and prescription charts—Mounjaro. But March 2026 marked a surprising moment: for the first time since its rapid rise, Mounjaro experienced a decline in monthly sales.

At the same time, semaglutide-based treatments surged ahead, gaining both volume and attention. This shift isn’t just about numbers—it signals a deeper transformation in how the weight-loss and diabetes treatment market is evolving in India.

Let’s break down what’s really happening, why it matters, and what it means for the future.

---

Understanding the Key Players: Mounjaro vs Semaglutide

Before diving into the numbers, it’s important to understand the two major drugs involved.

• Mounjaro (tirzepatide): A relatively newer drug that quickly became a blockbuster due to its strong weight-loss and blood sugar control effects.
• Semaglutide: A GLP-1 receptor agonist widely used for diabetes and weight management, now available in both branded and generic forms.

Semaglutide works by mimicking a natural hormone that regulates appetite and insulin, helping patients feel fuller for longer and control blood sugar levels.

While both drugs belong to the same broad category (GLP-1 therapies), their market dynamics are now diverging sharply.

---

What Happened in March 2026?

March brought a rare slowdown for Mounjaro.

• Sales dropped to around ₹114 crore, down from roughly ₹135 crore in February
• That’s a 16% decline month-on-month
• This marked the first significant drop since its launch phase

Meanwhile, semaglutide told a completely different story:

• Sales rose by 23% month-on-month
• Volume growth jumped sharply—by nearly 38%
• In some reports, injectable semaglutide volumes more than doubled within a month

Even more interesting? The overall GLP-1 market didn’t collapse. Instead, it grew—suggesting that Mounjaro didn’t lose demand entirely; it lost market share.

---

The Real Reason Behind Mounjaro’s Decline

This isn’t a story of failure—it’s a story of competition.

1. The Rise of Low-Cost Generics

The biggest disruption came from generic semaglutide.

After patent expiry in March 2026, multiple Indian pharmaceutical companies launched affordable versions of semaglutide.

These generics dramatically reduced treatment costs—making weight-loss therapies accessible to a much wider population.

In a price-sensitive market like India, this is a game changer.

---

2. Price Wars and Competitive Adjustments

To stay relevant, even original manufacturers began cutting prices.

This created a ripple effect:

• Lower prices → higher accessibility
• Higher accessibility → increased adoption
• Increased adoption → rapid volume growth

Semaglutide became the “mass-market” option, while Mounjaro started to look like a premium product.

---

3. Changing Prescription Patterns

Doctors and patients are increasingly making cost-benefit decisions.

Even if Mounjaro offers strong results, semaglutide’s affordability makes it a practical choice for long-term treatment.

As a result:

• Prescriptions began shifting
• Repeat usage favored cheaper options
• New patients leaned toward semaglutide

This explains why semaglutide volumes surged even as Mounjaro remained a top brand.

---

Mounjaro Is Still #1—But for How Long?

Despite the dip, Mounjaro still holds the crown as India’s top pharmaceutical brand by value.

Its annual sales remain strong, and it continues to dominate in terms of revenue.

However, cracks are beginning to show:

• Market share has started declining
• Volume growth has slowed
• Competitive pressure is intensifying

This raises an important question:

👉 Is this just a temporary correction—or the beginning of a long-term shift?

---

The Bigger Trend: Democratization of Weight-Loss Drugs

The real story goes beyond just two drugs.

India is entering a new era where:

• Advanced obesity treatments are becoming mainstream
• Costs are dropping significantly
• More patients are entering the treatment ecosystem

Earlier, these therapies were considered luxury or niche. Now, they’re becoming part of everyday healthcare.

This “democratization” is being driven by:

• Generic drug manufacturing
• Competitive pricing strategies
• Increasing awareness of obesity and diabetes

---

Why Semaglutide Is Winning the Volume Game

Semaglutide’s success isn’t accidental. It’s built on three strong pillars:

Accessibility

With generics entering the market, prices have dropped dramatically—making treatment affordable for middle-class patients.

Availability

Multiple companies are now producing semaglutide, ensuring widespread distribution across India.

Acceptance

Doctors are familiar with semaglutide, and it has a longer track record compared to newer drugs.

Together, these factors create a powerful growth engine.

---

But Is Cheaper Always Better?

While affordability is a major advantage, it also raises concerns.

• Quality consistency among generics
• Overuse without proper medical supervision
• Misuse for cosmetic weight loss

Globally, experts have already warned about the risks of unsupervised usage of weight-loss injections, including side effects and long-term health concerns.

This means the market growth must be balanced with responsible usage.

---

The Business Impact: A “Gold Rush” Phase

Industry experts describe the current situation as a “gold rush” in obesity drugs.

Here’s why:

• Patent expiries opened the floodgates
• Domestic pharma companies rushed in
• Competition intensified overnight

The result?

• Rapid innovation
• Aggressive pricing
• Fierce market competition

For pharmaceutical companies, this is both an opportunity and a challenge.

---

What This Means for Patients

For patients, this shift is largely positive.

Benefits:

• More affordable treatment options
• Increased access across cities and towns
• Greater awareness about obesity management

Risks:

• Self-medication without guidance
• Unrealistic expectations
• Short-term use without lifestyle changes

Ultimately, these drugs are tools—not magic solutions.

---

What Lies Ahead: Future of the GLP-1 Market in India

The Indian obesity drug market is expected to grow significantly over the next few years.

Here’s what we can expect:

1. Continued Price Pressure

Prices will likely keep falling as more generics enter the market.

2. Increased Competition

New molecules and therapies will enter the space, intensifying rivalry.

3. Market Expansion

More patients will adopt these treatments, expanding the overall market size.

4. Innovation Focus

Companies will focus on better formulations—oral drugs, longer-lasting injections, and combination therapies.

---

Final Thoughts: A Market in Transition

The dip in Mounjaro’s sales isn’t a sign of weakness—it’s a signal of change.

India’s pharmaceutical market is evolving rapidly:

• From premium to accessible
• From limited to widespread
• From monopoly to competition

Semaglutide’s rise shows how powerful affordability and accessibility can be in shaping healthcare trends.

Meanwhile, Mounjaro still holds strong—but it must adapt to this new reality.

In the end, the biggest winner might not be a single drug—but the millions of patients who now have better, more affordable treatment options.